Join our journey towards a better future

Discover the latest news, events, and updates on our collaborative endeavors. Stay informed about our ongoing work, upcoming events, and progress toward our shared goals. Embracing inclusivity, we unite partners from diverse sectors and disciplines to collectively shape the future.

Testbed Sweden PHC, Seminar Bomdia AB Testbed Sweden PHC, Seminar Bomdia AB

Webinarium 12/12 about Molecular Tumor Board Portal

Welcome to a webinar about Molecular Tumour Board Portal – decision support system for omics data in cancer treatment and clinical studies. The Molecular Tumor Board Portal (MTBP) has been developed within Janne Lehtiö's lab at Karolinska Institutet and serves as a decision support system for patient inclusion in the Basket of Baskets (BoB) study, conducted as part of the Cancer Core Europe collaboration.

Read More
Seminar, Resources Bomdia AB Seminar, Resources Bomdia AB

Watch our seminars from Almedalen

Vision Zero Cancer and Testbed Sweden Precision Health Cancer organized two events in Almedalen 2023. Almedalen takes place each year in Sweden in the city of Visby at the island of Gotland and is the world's largest democratic meeting place for social issues.

Read More
Seminar, Resources Bomdia AB Seminar, Resources Bomdia AB

Almedalen 2023

Vision Zero Cancer and Testbed Sweden Precision Health Cancer are organizing two events in Almedalen 2023. Almedalen takes place each year in Sweden in the city of Visby at the island of Gotland and is the world's largest democratic meeting place for social issues.

Read More
Seminar, Resources, Lung cancer, Early detection Bomdia AB Seminar, Resources, Lung cancer, Early detection Bomdia AB

Knowledge and experience exchange with Sweden: Early detection of lung cancer in never-smokers

Lung cancer accounts for one in five deaths worldwide. The past few years have seen considerable advances in treatment for lung cancer, yet the prognosis remains low. Lung cancer causes symptoms that come up late in the course of the disease and assessments are complicated. This means that half of the patients have a spread disease at diagnosis.

Read More